Importantly, 5FU-based combination treatment also shows an increase in mitochondrial mass (FOLFOX (5FU + 1 M oxaliplatin) or FOLFIRI (5FU + 5 nM SN38, active metabolite of irinotecan)) that we attribute to 5FU-imposed stress, given that single-agent oxaliplatin or SN38 do not promote the same degree of mitochondrial adaptation (Extended Data Fig
Lancet Infect Dis 12:210221
Up to now, powerful genetic tools allowed clarification of the significance, dispensability and potential of cystine transporters for ferroptotic cell death in PDAC and breast cancer ( via xCT ( A high extracellular glutamate concentration was one of the first xCT inhibitors described but a few years later, erastin (standing for eradicator of RAS and small T antigen-expressing cells) was identified by Stockwell's group in RAS-mutated cancer cell lines as inhibitor of xCT transport ( in vitro studies as efficient inducer of ferroptosis in many different cancer types, including breast, PDAC, lymphoma, renal, brain and ovarian cancers ( via transsulfuration pathway is a potential resistance mechanism under cysteine depletion conditions
Your body needs time to adjust to the medication, and pushing too hard can trigger severe nausea [5], vomiting, or digestive upset